MedTrace Logo

NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers.

NCT00318266 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 73

Last updated 2017-08-25

No results posted yet for this study

Summary

It is hypothesized that the NMP22(Nuclear Matrix Protein) Bladder Check ® Test will demonstrate improved sensitivity over that of standard urine cytology for patients with superficial transitional cell carcinoma at high risk of recurrence.

Conditions

Interventions

DEVICE

Nuclear Matrix Protein 22 Urine sample kit

Urine sample obtained from patient will be tested with the NMP22 sample kit to see if it can detect bladder cancer.

Sponsors & Collaborators

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Principal Investigators

  • Jonathan Izawa, MD FRCSC · Western University, Canada

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00318266 on ClinicalTrials.gov